Case 4: SRS Versus Whole Brain Radiation Therapy

Video

EXPERT PERSPECTIVE VIRTUAL TUMOR BOARD

Benjamin P. Levy, MD:Anshu, this patient, as I recall, had 2 brain METS [metastases]. Clearly, management of brain METS has evolved. We have data now that targeted therapies may cross the blood-brain barrier and may circumvent the need for radiation. We have some soft data on immunotherapy. Maybe it crosses the blood-brain barrier? What is your role in managing this? How you manage them—SRS [stereotactic radiosurgery], CyberKnife. Walk us through that.

Anshu K. Jain, MD: Sure. We often will look at this on a patient-by-patient basis. In the up-front setting, if the patient has brain METS on diagnosis, and certainly I think when you’re looking at a case where you’re dealing with 3 or fewer METS, we typically like to at least have an evaluation for surgical resection. I think that if they could come out, that’s the best way to go.

I think that the paradigm has really changed, moving away from whole brain radiation therapy, even in the setting of up to 3 METS. We typically favor up-front stereotactic radiosurgery [SRS] for these patients. In experienced hands, this can be done fairly quickly. It results in fairly predictable and low rates of toxicity. Also, I think it allows us to keep those options, in terms of any type of cross-brain barrier activity that a systemic therapy may have. I think we like to think about it more in terms of helping to prevent relapse as opposed to treating existing METS.

Benjamin P. Levy, MD:Yeah. How often do you surveil the brain after you have completed radiosurgery? Do you talk to your medical oncologist? We’ve done the radiation, or our SRS every 3 months, every 6 months. How often do you monitor the patient?

Anshu K. Jain, MDDuring year 1, we like to do every 3 months with MRI [magnetic resonance imaging] surveillance. That seems to be what practice patterns typically bear out—about every 3 months. Some practitioners will get a post-SRS MRI of the brain at 6 weeks and then have that as a baseline to assess from in the future.

Transcript edited for clarity.


Recent Videos
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
Related Content